ENDRA Life Sciences Inc. (NASDAQ:NDRA) Sees Significant Growth in Short Interest

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 44,700 shares, a growth of 41.5% from the March 31st total of 31,600 shares. Approximately 8.0% of the shares of the company are short sold. Based on an average daily volume of 118,200 shares, the days-to-cover ratio is presently 0.4 days.

ENDRA Life Sciences Stock Performance

ENDRA Life Sciences stock opened at $6.14 on Friday. The firm’s 50 day moving average price is $4.14 and its two-hundred day moving average price is $5.40. The firm has a market cap of $3.45 million, a PE ratio of -0.01 and a beta of 0.19. ENDRA Life Sciences has a twelve month low of $2.97 and a twelve month high of $602.00.

ENDRA Life Sciences (NASDAQ:NDRA) last posted its earnings results on Monday, March 31st. The company reported ($9.40) earnings per share for the quarter, missing the consensus estimate of ($4.10) by ($5.30). Equities analysts anticipate that ENDRA Life Sciences will post -47.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets decreased their price target on ENDRA Life Sciences from $75.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, April 21st.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.